Market Closed -
Nasdaq
04:00:00 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
3.54
USD
|
-2.48%
|
|
+1.72%
|
+139.19%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9.601
|
635.5
|
252.2
|
62.55
|
66.12
|
158.3
|
-
|
-
|
Enterprise Value (EV)
1 |
9.601
|
635.5
|
252.2
|
62.55
|
66.12
|
158.3
|
158.3
|
158.3
|
P/E ratio
|
-0.44
x
|
-16.7
x
|
-8.23
x
|
-1.57
x
|
-1.59
x
|
-3.62
x
|
-3.34
x
|
-2.66
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
39.2
x
|
1,736
x
|
703
x
|
162
x
|
135
x
|
406
x
|
2,375
x
|
2,375
x
|
EV / Revenue
|
39.2
x
|
1,736
x
|
703
x
|
162
x
|
135
x
|
406
x
|
2,375
x
|
2,375
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-38.5
x
|
-10.8
x
|
-1.57
x
|
-2.1
x
|
-3.04
x
|
-1.67
x
|
-0.81
x
|
FCF Yield
|
-
|
-2.6%
|
-9.22%
|
-63.8%
|
-47.6%
|
-32.8%
|
-60%
|
-123%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
7,742
|
35,325
|
41,964
|
44,677
|
44,677
|
44,725
|
-
|
-
|
Reference price
2 |
1.240
|
17.99
|
6.010
|
1.400
|
1.480
|
3.540
|
3.540
|
3.540
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.245
|
0.366
|
0.359
|
0.386
|
0.488
|
0.39
|
0.0667
|
0.0667
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-16.68
|
-19.09
|
-28.86
|
-39.9
|
-45.41
|
-46.88
|
-58.37
|
-77.94
|
Operating Margin
|
-6,807.35%
|
-5,214.86%
|
-8,037.6%
|
-10,337.31%
|
-9,305.74%
|
-12,020.77%
|
-87,545.63%
|
-116,904.15%
|
Earnings before Tax (EBT)
1 |
-16.41
|
-19.31
|
-28.29
|
-38.7
|
-41.44
|
-45.24
|
-57.9
|
-78.14
|
Net income
1 |
-16.71
|
-22.6
|
-28.32
|
-38.73
|
-41.46
|
-45.25
|
-57.91
|
-78.14
|
Net margin
|
-6,819.18%
|
-6,174.32%
|
-7,887.19%
|
-10,033.16%
|
-8,496.93%
|
-11,602.37%
|
-86,857.66%
|
-117,204.14%
|
EPS
2 |
-2.800
|
-1.080
|
-0.7300
|
-0.8900
|
-0.9300
|
-0.9775
|
-1.060
|
-1.330
|
Free Cash Flow
1 |
-
|
-16.53
|
-23.24
|
-39.9
|
-31.47
|
-52
|
-95
|
-195
|
FCF margin
|
-
|
-4,515.65%
|
-6,474.93%
|
-10,337.31%
|
-6,448.57%
|
-13,333.33%
|
-142,492.88%
|
-292,485.38%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.133
|
0.074
|
0.091
|
0.093
|
0.128
|
0.083
|
0.108
|
0.141
|
0.156
|
0.205
|
0.0588
|
0.0625
|
0.0662
|
0.025
|
0.025
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.526
|
-11.07
|
-10.44
|
-8.993
|
-9.392
|
-12.05
|
-12.21
|
-10.82
|
-10.33
|
-10.93
|
-11.45
|
-12.07
|
-12.42
|
-13.52
|
-13.52
|
Operating Margin
|
-7,162.41%
|
-14,964.86%
|
-11,475.82%
|
-9,669.89%
|
-7,337.5%
|
-14,520.48%
|
-11,303.7%
|
-7,673.76%
|
-6,623.08%
|
-5,333.17%
|
-19,488.09%
|
-19,317.2%
|
-18,742.26%
|
-54,100%
|
-54,100%
|
Earnings before Tax (EBT)
1 |
-9.442
|
-10.99
|
-10.44
|
-8.571
|
-8.697
|
-11.22
|
-11.15
|
-9.731
|
-9.337
|
-10.01
|
-11.21
|
-11.84
|
-12.18
|
-13.42
|
-13.42
|
Net income
1 |
-9.448
|
-11
|
-10.45
|
-8.577
|
-8.721
|
-11.23
|
-11.16
|
-9.737
|
-9.343
|
-10.02
|
-11.21
|
-11.84
|
-12.19
|
-13.43
|
-13.43
|
Net margin
|
-7,103.76%
|
-14,863.51%
|
-11,482.42%
|
-9,222.58%
|
-6,813.28%
|
-13,528.92%
|
-10,329.63%
|
-6,905.67%
|
-5,989.1%
|
-4,886.34%
|
-19,086.38%
|
-18,946%
|
-18,394.34%
|
-53,724%
|
-53,724%
|
EPS
2 |
-0.2500
|
-0.2500
|
-0.2400
|
-0.2000
|
-0.2000
|
-0.2500
|
-0.2500
|
-0.2200
|
-0.2100
|
-0.2200
|
-0.2475
|
-0.2600
|
-0.2450
|
-0.2900
|
-0.2900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
5/5/22
|
8/4/22
|
11/3/22
|
3/2/23
|
5/4/23
|
8/9/23
|
11/2/23
|
2/29/24
|
5/2/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-16.5
|
-23.2
|
-39.9
|
-31.5
|
-52
|
-95
|
-195
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
0.21
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
57.89%
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/24/22
|
3/2/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
3.54
USD Average target price
9.833
USD Spread / Average Target +177.78% Consensus |
1st Jan change
|
Capi.
|
---|
| +139.19% | 158M | | +41.79% | 54.04B | | -0.56% | 41.92B | | +48.77% | 41.96B | | -7.20% | 28.35B | | +12.59% | 26.35B | | -21.51% | 19B | | +6.92% | 13B | | +24.91% | 12.19B | | +29.60% | 12.28B |
Other Biotechnology & Medical Research
|